Contact
Please use this form to send email to PR contact of this press release:
Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
TO:
Please use this form to send email to PR contact of this press release:
Ocuphire Pharma Announces First Patient Enrolled in MIRA-2 Phase 3 Clinical Trial Investigating Nyxol® for Reversal of Mydriasis
TO: